Invex Therapeutics (ASX:IXC) Equity-to-Asset : 0.92 (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Invex Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Invex Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2024 was A$5.38 Mil. Invex Therapeutics's Total Assets for the quarter that ended in Dec. 2024 was A$5.86 Mil.

The historical rank and industry rank for Invex Therapeutics's Equity-to-Asset or its related term are showing as below:

ASX:IXC' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.84 Med: 0.95 Max: 0.98
Current: 0.92

During the past 5 years, the highest Equity to Asset Ratio of Invex Therapeutics was 0.98. The lowest was 0.84. And the median was 0.95.

ASX:IXC's Equity-to-Asset is ranked better than
87.97% of 1488 companies
in the Biotechnology industry
Industry Median: 0.68 vs ASX:IXC: 0.92

Invex Therapeutics Equity-to-Asset Historical Data

The historical data trend for Invex Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invex Therapeutics Equity-to-Asset Chart

Invex Therapeutics Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

Jun24

Equity-to-Asset

0.92

0.98

0.97

0.93

Invex Therapeutics Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Equity-to-Asset	Get a 7-Day Free Trial						0.96	0.93	0.84	0.93	0.92

Competitive Comparison of Invex Therapeutics's Equity-to-Asset

For the Biotechnology subindustry, Invex Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Invex Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Invex Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Invex Therapeutics's Equity-to-Asset falls into.

Save Embed

;

Save Embed

;

Invex Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Invex Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Jun. 2024 is calculated as

Equity to Asset (A: Jun. 2024 )	=	Total Stockholders Equity	/	Total Assets
	=	5.688	/	6.12
	=

Invex Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

Equity to Asset (Q: Dec. 2024 )	=	Total Stockholders Equity	/	Total Assets
	=	5.384	/	5.864
	=

Invex Therapeutics (ASX:IXC) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Invex Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Invex Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Invex Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Invex Therapeutics Ltd (ASX:IXC) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

38 Rowland Street, Level 1, Subiaco, WA, AUS, 6008

Website

https://www.invextherapeutics.com

Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.